Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice

Publisher： Karger

E-ISSN： 1421-9875|33|5|668-674

ISSN： 0257-2753

Source： Digestive Diseases, Vol.33, Iss.5, 2015-09, pp. : 668-674

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Characteristics and Quality of Randomized Controlled Trials in the Treatment of Hepatocellular Carcinoma

By Kaido Toshimi  

Digestive Diseases and Sciences, Vol. 52, Iss. 4, 2007-04 ,pp. : 1108-1113

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Trials in Hepatocellular Carcinoma: An Update

By  

Liver Cancer, Vol. 2, Iss. 3-4, 2013-08 ,pp. : 345-364

Karger

Access to resources Recommend Favorite

Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience

By  

Digestive Diseases, Vol. 30, Iss. 6, 2012-12 ,pp. : 609-616

Karger

Access to resources Recommend Favorite

Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis

By  

Digestive Diseases, Vol. 33, Iss. 6, 2015-0 ,pp. : 728-734

Karger

Access to resources Recommend Favorite

Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials

By  

Liver Cancer, Vol. 5, Iss. 3, 2016-05 ,pp. : 162-174

Karger

Access to resources Recommend Favorite